Innovative GDH-FAD Enzyme Improves Accuracy in Blood Glucose Meters

Rising Diabetes Burden and the Demand for Accuracy

Nowadays, diabetes is spreading rapidly and even affecting younger people. Many young individuals have developed diabetes due to poor dietary habits. In China alone, the number of adults aged 20–79 living with diabetes reached 141 million by 2023, making accurate blood glucose monitoring more critical than ever.

Self-monitoring of blood glucose (SMBG) is a cornerstone of effective diabetes management, enabling patients to make informed lifestyle and treatment decisions. Most SMBG devices use portable blood glucose meters based on two primary enzymatic methods:

Glucose Oxidase (GOD) – Highly specific but susceptible to oxygen interference, making it unsuitable for patients with unstable blood oxygen levels.
Glucose Dehydrogenase (GDH) – Oxygen-independent, but prone to interference from sugars such as maltose, galactose, and xylose, which can cause false readings.

To overcome these challenges, innovation in glucose dehydrogenase enzymes is essential.

Features

Newly Upgraded Glucose Dehydrogenase

Enzyme sequence mutation enhances stability

Through the introduction of a series of mutation points, enzyme stability has been significantly improved.

Optimized lyophilized formulation improves adaptability

To reduce interference, a version without lyophilization protectants (only basic buffer solution included) has been developed. Both lyophilized and non-lyophilized versions are available to improve compatibility with various systems.

Outstanding Performance

Excellent substrate selectivity with strong anti-interference ability

Almost no reaction with xylose or other sugars. When diabetic patients take or are injected with xylose-containing formulations, this helps reduce false glucose readings caused by sugar interference.

Wider pH range enhances reagent compatibility

Performs excellently across a pH range of 2.0–10.0, making it suitable for more systems and application scenarios.

Strong chemical tolerance broadens formulation potential

Tolerant to various chemical substances, with strong anti-interference capabilities in complex samples, and enables the development of more reagent formulations.

Data

Enzyme sequence mutation improves enzyme stability

Thermostability has been enhanced, improving the performance of reagents and test strips.

Optimized lyophilized formulation enhances enzyme adaptability

To reduce interference from external substances, a version without lyophilization protectants has been specifically developed.

Excellent substrate selectivity improves anti-interference performance

Effectively excludes interference from xylose, maltose, mannose, galactose, and other sugars.

Wider pH range enhances reagent adaptability

The enzyme demonstrates excellent activity under extreme pH conditions.

Strong tolerance broadens formulation potential

Tolerant to various surfactants and metal ions; compared to similar products, it shows stronger anti-interference ability against Ag and Zn ions.

Table1: The enzyme dissolved in 50 mM K-phosphate buffer (pH6.0) was incubated with each chemical at 25'c for 1hr. Enzyme concentration: 50 U/mL.

Transforming Blood Glucose Monitoring Technology

The newly upgraded Hzymes GDH-FAD enzyme is designed for the next generation of blood glucose test strips, delivering higher accuracy, fewer false positives, and better system compatibility. By reducing interference and improving performance across a wider range of conditions, it empowers both manufacturers and healthcare providers to offer more reliable testing solutions.

For patients, this means more accurate readings, better treatment decisions, and improved quality of life—a critical step forward in diabetes care.

Conclusion – Setting a New Benchmark for GDH-FAD Enzymes

With its unique combination of stability, selectivity, and adaptability, Hzymes’ upgraded GDH-FAD enzyme represents a significant leap in diabetes monitoring technology. As the global diabetes burden grows, innovative enzyme solutions like this will be key to improving self-monitoring accuracy and supporting better patient outcomes.